CNR1 and neoplasm: CXCR3 ligands have been demonstrated to decrease tumor advancement by indirectly mediating anti-angiogenic effects, while the cannabinoid receptors CB1 and CB2 have been shown to suppress tumor progression in a variety of malignancies, including gliomas, breast, colorectal, and skin cancers [215].